NCT06010628View on ClinicalTrials.gov

Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,440

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 15, 2026

Study Completion Date

December 15, 2026

Conditions
Stroke, Ischemic
Interventions
DRUG

Tenecteplase

intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).

Trial Locations (2)

110016

RECRUITING

Department of Neurology, General Hospital of Northern Theater Command, Shenyang

110840

RECRUITING

Hui-Sheng Chen, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER